Latest news with #OrganCareSystem
Glasgow Times
30-07-2025
- Health
- Glasgow Times
New NHS Golden Jubilee class helps heart transplant patients
Launched by the NHS Golden Jubilee, the physiotherapy-led class is designed for patients on the heart transplant waiting list to help maintain their fitness ahead of surgery. The sessions focus on improving physical strength, cardiovascular health, and mental well-being, all in a safe and supportive environment. Eireann Murray, a physiotherapist at NHS Golden Jubilee, said: "The aim is to encourage patients to leave the ward, engage in activities, and connect with others who are on a similar journey. "All patients are welcome to join, and participation is entirely voluntary – no one is expected to do anything they're uncomfortable with." The programme is part of the Scottish National Advanced Heart Failure Service (SNAHFS), based at the Golden Jubilee, which delivers specialist therapies to patients across Scotland. In 2024/25, SNAHFS carried out 29 heart transplants, following a record-breaking year in 2023/24. So far this year, nine transplants have been performed, with more planned in the coming months. Patients who take part in the exercise class report benefits that go beyond the physical. Andy Gordon, a patient who is participating in the programme, praised the class's straightforward exercises. He had a heart attack in June 2023 and was referred to NHS Golden Jubilee from the Edinburgh Royal Infirmary, where he was told he needed a transplant. Andy said: "I would feel lost without coming to these classes twice a week. "The exercises are clear, simple, and easy to understand – the more you attend, the more you improve. "Having an issue which affects your heart knocks your confidence as you don't know how much to push yourself, but with the physios here, they build you up and keep you safe." The class also provides a valuable opportunity for social interaction, helping to reduce isolation and build emotional resilience during a difficult period. Mitchell Lindsay, associate medical director at NHS Golden Jubilee, said: "This programme is a vital part of NHS Golden Jubilee's commitment to person-centred care. "It provides tailored support to help individuals improve their fitness, achieve their goals, and feel a sense of connection as they prepare for life-saving and life-changing transplant surgery." Patients receive lifelong aftercare from the SNAHFS team after their transplant. Innovations such as the Organ Care System, also known as Heart in a Box, have improved heart donation opportunities. This technology has contributed to a 95% 90-day survival rate for transplant patients.
Yahoo
18-06-2025
- Business
- Yahoo
TransMedics (TMDX) Continues to Scale Innovation in Organ Transplant Care
TransMedics Group Inc. (NASDAQ:TMDX) is one of the 10 best growth stocks to buy according to billionaires. The stock has had a tremendous year so far, with share price gains of 129%, leading other stocks in this list by a considerable margin, as none of the other stocks here have even reached 100%. In 2024, the company's revenue surged a robust 83%, and the street expects it to post a solid 31% growth in FY 2025. The company is also likely to experience significantly improved profitability, as consensus EPS forecasts a 77% growth this year and a 38% growth next year. A doctor performing a living donor kidney transplant in a hospital operating room, emphasizing the importance of medical advancements. On June 9, Canaccord Genuity analyst William Plovanic reaffirmed a Buy rating on TransMedics Group Inc. (NASDAQ:TMDX) with an unchanged price target of $129. This reaffirmation follows the company's June 9 presentation at the Goldman Sachs Global Healthcare Conference, where the company reaffirmed the strategy behind its industry-leading position in organ transplantation. Its execution continues to support a positive outlook, with management sharing tangible progress toward its long-term targets. At the centre of the story is the National OCS Program (NOP), which now drives nearly all company revenue, enabling TransMedics to offer a full-service, end-to-end transplant logistics and technology solution. This model has not only boosted transplant volumes but also established a critical advantage that competitors have yet to replicate. The company is targeting $1.2 billion in revenue and a 30% operating margin by 2028, driven by the expanded adoption of its Organ Care System and the upcoming next-generation platforms. Notably, its leadership in the DCD (donation after circulatory death) heart category, which now makes up about half of all U.S. heart donors, reflects its role in expanding the donor pool. TransMedics Group Inc. (NASDAQ:TMDX) is well-positioned to introduce new platforms for heart, lung, and kidney care in the coming years, including a Gen 3 system designed for greater portability and scalability. With strong clinical data and operational depth, the company appears well-positioned to hit its 10,000 annual transplants milestone by 2028 and continue growing from there. Management expects its kidney platform to launch by 2027 and aims to achieve 20,000 to 30,000 transplants over the next three to five years. TransMedics Group Inc. (NASDAQ:TMDX) is a commercial-stage medical technology company offering organ transplant therapy for patients with end-stage organ failure across multiple disease states. While we acknowledge the potential of TMDX as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money. Disclosure: None. Sign in to access your portfolio
Yahoo
15-05-2025
- Business
- Yahoo
2 Brilliant Stocks to Buy With $200 and Hold for 5 Years
TansMedics Group is helping improve patient outcomes in the organ transplant field. Exact Sciences has helped increase colorectal cancer detection. 10 stocks we like better than TransMedics Group › While being an innovative company doesn't guarantee superior long-term returns, it doesn't hurt those chances either. In fact, when a corporation is making important breakthroughs and boasts significant growth prospects in its industry, that could translate to above-average stock market performances over five years or more. That description fits TransMedics Group (NASDAQ: TMDX) and Exact Sciences (NASDAQ: EXAS), two innovative healthcare leaders. Here's why these companies could deliver strong returns through the end of the decade. TransMedics Group developed a revolutionary way to store organs before transplants. The company's Organ Care System (OCS) mimics the physiology of the human body, resulting in a higher usage rate for the organs it is approved for -- lungs, hearts, and kidneys -- than the traditional cold storage method. In a clinical trial, 32% of hearts kept in cold storage were used in a transplant, versus 81% for the OCS. The company's technology is superior; that's why it has gained traction. TransMedics Group has encountered some issues recently. The company's revenue growth slowed, while its guidance disappointed investors. Further, the medical device specialist became the target of serious allegations from an activist short-seller. However, TransMedics Group is rebounding, partly thanks to recent stronger-than-expected first-quarter results. TransMedics Group's stock jumped by about 20% on the heels of its most recent quarterly update. Still, the company's shares remain down by 11% in the past year, and there could be significant upside potential for the company in the next five years. TransMedics Group estimates that deceased donations of organs will continue to increase in the next few years. Meanwhile, there are more people in need of organs than the number of those willing to donate theirs. For the ones available, keeping them in the best possible shape for transplants is incredibly important. TransMedics Group's OCS is one of the better options on the market for doing just that. So, the company should continue growing its revenue and earnings at a good clip in the next five years, and likely beyond that. And in the meantime, the company could deliver excellent returns to investors. Investors can buy one of TransMedics Group's shares at current levels with $200. Exact Sciences is a healthcare company that develops cancer diagnostic tests. The company is best known for Cologuard, a non-invasive, at-home test for colorectal cancer (CRC) -- the second leading cause of cancer death worldwide. The fact that the disease is highly treatable when caught early, and yet kills as many patients as it does, suggests that not enough eligible people are getting screened. For those at average risk of CRC, it is recommended to start screening at 45 years old. Exact Sciences has made significant headway in this market. It first earned clearance for Cologuard in the U.S. in 2014; by 2022, it had been used to screen 10 million patients. Exact Sciences has encountered some headwinds in the past few years, including slower revenue growth and persistent net losses. However, recent developments could help the company fix this issue. In October, it earned approval for the next-gen version of its crown jewel, Cologuard Plus. This newer test proved superior at identifying true positives and false negatives, and should, therefore, help attract even more prescriptions from otherwise skeptical physicians. The new Cologuard is also 5% cheaper to manufacture. That should make a meaningful difference in the company's costs across millions of tests. Further, Exact Sciences recently launched Oncodetect, which is designed to check for cancer recurrence in patients across several solid tumors. Lastly, Exact Sciences plans to debut another product later this year, a multicancer-detecting test called Cancerguard. With these new products and the company's well-established Cologuard franchise, expect stronger revenue growth and, eventually, net profits before the end of the decade. The stock could deliver superior returns. Exact Sciences' shares are trading hands for just under $54, so $200 is good for three. Before you buy stock in TransMedics Group, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and TransMedics Group wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $598,613!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $753,878!* Now, it's worth noting Stock Advisor's total average return is 922% — a market-crushing outperformance compared to 169% for the S&P 500. Don't miss out on the latest top 10 list, available when you join . See the 10 stocks » *Stock Advisor returns as of May 12, 2025 Prosper Junior Bakiny has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends TransMedics Group. The Motley Fool recommends Exact Sciences. The Motley Fool has a disclosure policy. 2 Brilliant Stocks to Buy With $200 and Hold for 5 Years was originally published by The Motley Fool
Yahoo
09-05-2025
- Business
- Yahoo
Why TransMedics Stock Is Skyrocketing Today
TransMedics delivered revenue and net income growth of 48% and 111% in its first-quarter earnings. The company continues to see streamlining efficiencies from its nascent logistical network. Solidly profitable and with a promising growth story, TransMedics remains one of my favorite investments. 10 stocks we like better than TransMedics Group › Shares of next-generation transplant technology platform TransMedics (NASDAQ: TMDX) were up 21% as of noon ET on Friday, according to data provided by S&P Global Market Intelligence. TransMedics reported first-quarter results that saw revenue balloon 48% and the company's net income margin rise from 13% a year ago to 18% today. On top of these results blowing away analysts' expectations, management raised its 2025 sales guidance from 23% at the midpoint to 30%, sparking an optimistic reaction from the market. TransMedics' Organ Care System (OCS) and National OCS Platform (NOP) have moved the organ transplant industry into a new era. As opposed to the less-effective, traditional ice storage previously used in transplants, the company's OCS keeps livers, hearts, and lungs perfused with blood and functioning while in transit to a donee. While this upgrade alone allows for longer travel time for donated organs (and higher success rates), TransMedics took things to the next level when it started to buy planes for its logistics services in 2023. Immediately put to use in 49% of NOP flight missions in Q1 of 2024, the company's planes now cover 78% of these flights in Q1 2025. This streamlining logistical network helped TransMedics' net income spike 111% from last year and makes the company a true end-to-end solution for organ transplants. However, just because TransMedics has seemingly reached new levels of profitability, don't think its growth days are over. Transplanting 3,715 organs in 2024 -- and I'd guess somewhere slightly above 1,000 in Q1 -- the company believes it can grow to 10,000 transplants by 2028. With its next-gen lung and heart systems -- the company's smaller segments -- set to enter clinical trials later this year, TransMedics should have plenty of growth ahead. Before you buy stock in TransMedics Group, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and TransMedics Group wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $617,181!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $719,371!* Now, it's worth noting Stock Advisor's total average return is 909% — a market-crushing outperformance compared to 163% for the S&P 500. Don't miss out on the latest top 10 list, available when you join . See the 10 stocks » *Stock Advisor returns as of May 5, 2025 Josh Kohn-Lindquist has positions in TransMedics Group. The Motley Fool has positions in and recommends TransMedics Group. The Motley Fool has a disclosure policy. Why TransMedics Stock Is Skyrocketing Today was originally published by The Motley Fool Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
24-04-2025
- Business
- Yahoo
1 Beaten-Down Stock to Buy Right Now and Hold for a Decade
President Donald Trump's trade war is creating significant uncertainty. Equities plunged following his decision to impose tariffs on almost every country, then soared after he announced a 90-day pause on his expanded tariff plans. It's challenging to predict which way the market will move next, but in times like these, it helps to invest in companies that look likely to perform well in the long run. Consider the case of TransMedics Group (NASDAQ: TMDX), a medical technology company whose shares have declined by 31% over the past six months. Let's find out why it's worth it to buy this company's shares and hold on to them for the next decade. Where to invest $1,000 right now? Our analyst team just revealed what they believe are the 10 best stocks to buy right now. Continue » First, let's review what TransMedics does. The company developed a device called the Organ Care System (OCS) to help store donor organs -- not a simple thing to do. Once they're removed from their natural habitat (the human body), organs deteriorate quickly, making them unusable for transplants. There are already far more patients in need of donor organs than the number of people willing to donate, so keeping the ones that are available in a healthy condition is of the utmost importance. While other options exist, TransMedics' OCS mimics the physiology of the human body, helping organs stay in good shape and remain ready for transplant longer. The U.S. Food and Drug Administration has approved the company's OCS to preserve lungs, hearts, and livers for transplants. TransMedics typically generates strong revenue, and it finally turned in a profit last year: Why, then, have TransMedics shares dropped lately? There are three main reasons. First, the company's latest updates, particularly for the third quarter, came in short of analyst expectations. Second, in December, it lowered its guidance for the fourth quarter, which came as a disappointment to investors. Lastly, short-seller Scorpion Capital published a highly critical report questioning the company's practices. While TransMedics quickly issued a denial, the stock still plunged following these developments. Despite these headwinds, it might be worth it to buy TransMedics shares today and hold on to them for the next decade. Here's why. One factor that could drive TransMedics Group's results over the next 10 years is growth in the number of organ donors. Another is the company's superior technology, which helps improve outcomes. Let's address each of these factors. First, an organ transplant is often needed to treat end-stage organ failure. But since we're talking about vital organs, most living humans aren't going to be quick to volunteer to donate their own, even when they can -- it's feasible for kidneys, but not so much for hearts. Even so, the number of people who donate after death has increased in recent years. In the U.S., this trend is expected to continue for the foreseeable future. TransMedics sees a compound annual growth rate of 5% as a conservative estimate, and 12% for the optimistic projection, through 2028. This is good for both patients and TransMedics' business. Second, the traditional method of storing organs before transplants -- cold storage -- comes with significant limitations. Cold storage can quickly damage organ tissue, making it unusable for transplants, among other problems. TransMedics' approach leads to much higher utilization rates for available organs. For instance, within the lung transplant space, only 23% of donated organs kept through cold storage end up being used -- but 87% of those stored through TransMedics' OCS are utilized for transplants. That's a massive difference, which points to TransMedics' ability to grab an increasingly higher share of this market while increasing its revenue and earnings. What should investors make of the recent issues it encountered? Slowing revenue growth is almost inevitable as a company matures. Perhaps this justifies the recent sell-off TransMedics experienced, but the stock is now almost as cheap as it's been in three years: Finally, note that you should always take the word of short-sellers -- who make money from a company's share price dropping -- with a grain of salt. Without convincing evidence that TransMedics is guilty as charged, it's best to ignore the noise. In my view, this healthcare stock remains a top pick for investors who are willing to stay the course over the next decade. If you initiate a position at current levels, TransMedics Group could deliver excellent results. Before you buy stock in TransMedics Group, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and TransMedics Group wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $561,046!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $606,106!* Now, it's worth noting Stock Advisor's total average return is 811% — a market-crushing outperformance compared to 153% for the S&P 500. Don't miss out on the latest top 10 list, available when you join . See the 10 stocks » *Stock Advisor returns as of April 21, 2025 Prosper Junior Bakiny has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends TransMedics Group. The Motley Fool has a disclosure policy. 1 Beaten-Down Stock to Buy Right Now and Hold for a Decade was originally published by The Motley Fool Sign in to access your portfolio
